Every Peptide. Every Trial. Zero Hype.

A small-molecule NNMT inhibitor (technically not a peptide) grouped with peptides in fat-loss contexts, investigated in preclinical obesity and muscle-aging models.

Abaloparatide (trade name Tymlos) is a 34-amino acid synthetic peptide analog of human parathyroid hormone-related protein (PTHrP) approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It selectively activates the PTH1 receptor in its RG (G-protein-dependent) conformation, promoting robust anabolic bone formation with comparatively less bone resorption and hypercalcemia than teriparatide (PTH 1–34). In the pivotal ACTIVE trial, abaloparatide demonstrated significant reductions in vertebral and nonvertebral fractures, establishing it as a potent osteoanabolic agent in the management of severe osteoporosis.

A GnRH antagonist decapeptide that suppresses testosterone immediately without the initial flare of GnRH agonists. It was FDA-approved in 2003 for advanced prostate cancer but voluntarily withdrawn from the US market in 2005; it illustrates the antagonist approach later refined by degarelix.